Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

2.75
-0.0850-3.00%
Volume:7.45M
Turnover:20.60M
Market Cap:916.65M
PE:-2.22
High:2.84
Open:2.78
Low:2.70
Close:2.83
Loading ...

Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

GlobeNewswire
·
03 May

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Is Expected To Breakeven In The Near Future

Simply Wall St.
·
02 May

Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

GlobeNewswire
·
24 Apr

Is Iovance Biotherapeutics (IOVA) the Most Promising Penny Stock According to Analysts?

Insider Monkey
·
19 Apr

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
19 Apr

Iovance Biotherapeutics Is Maintained at Buy by Goldman Sachs

Dow Jones
·
18 Apr

Is Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Insider Monkey
·
16 Apr

Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
15 Apr

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
15 Apr

Iovance Biotherapeutics (NasdaqGM:IOVA) Drops 10% Over The Week In Market Correction

Simply Wall St.
·
05 Apr

Traws Pharma Announces Management Updates

GlobeNewswire
·
29 Mar

Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance

Simply Wall St.
·
05 Mar

Stock Track | Iovance Biotherapeutics Plummets 5.17% as Chardan Cuts Price Target on Mixed Q4 Results

Stock Track
·
04 Mar

Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan

TipRanks
·
04 Mar

Stock Track | Iovance Biotherapeutics Plummets 5.08% After Analysts Cut Price Targets

Stock Track
·
04 Mar

Iovance Biotherapeutics price target lowered to $15 from $25 at Truist

TIPRANKS
·
03 Mar

Stock Track | Iovance Biotherapeutics Soars 5.31% as Analysts Reaffirm "Buy" Ratings

Stock Track
·
03 Mar

Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating

MT Newswires Live
·
03 Mar

Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
03 Mar

Iovance Biotherapeutics (IOVA) Gets a Buy from Truist Financial

TIPRANKS
·
03 Mar